Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3340-3345

  Eggert, Andreas A O ^a   Schreurs, Marco W J ^a   Boerman, Otto C ^a   Oyen, Wim J C ^a   De Boer, Annemiek J ^a   Punt, Cornelis J A ^a   Figdor, Carl G ^a   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDIUM 111; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CANCER PATIENT; DENDRITIC CELL; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; LYMPH NODE; LYMPHOID CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL MOVEMENT; DENDRITIC CELLS; IMMUNIZATION SCHEDULE; IMMUNOTHERAPY, ACTIVE; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTRAMOLECULAR OXIDOREDUCTASES; LYMPH NODES; LYMPHOID TISSUE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033565923     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.
2. Hart, D. N. J. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90: 3245-3287, 1997.
3. Inaba, K., Metlay, J. P., Crowely, M. T., and Steinman, R. M. Dendritic cells pulsed with protein antigen in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med., 172: 631-640, 1990.
4. Inaba, K., Inaba, M., Romani, N., Aya, H, Deguchi, M., Ikehara, S., Muramatsu, S., and Steinman, R. M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 176: 1693-1702, 1992.
5. Reid, C. D., Stackpoole, A., Meager, A., and Tikerpae, J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J. Immunol., 149: 2681-2688, 1992.
6. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin4 and down-regulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
7. Siena, S., Di Nivola, M., Bregni, M., Motarini, R., Anichini, A., Lombardi, L., Ravagnani F., Parmiani, G., and Gianni, A. M. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp. Hematol., 23: 1463-1471, 1995.
8. Bakker, A. B. H., Marland, G., de Boer, A. J., Huijbens, R. J., Danen, E. H., Adema, G. J., and Figdor, C. G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55: 5330-5334, 1995.
9. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
10. Schreurs, M. W. J., de Boer, A. J., Schmidt, A., Figdor, C. F., and Adema, G. J. Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100. Melanoma Res., 7: 463-470, 1997.
11. Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., el-Gamil, M., Rosenberg, S. A., and Yang, J. C. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med., 185: 453-459, 1997.
12. Rolink, A., Melchers, F., Andersson, J. The SCID but the RAG-2 gene product is required for Sμ-S∈ heavy chain class switching. Immunity, 5: 319-330, 1996.
13. Fidler, I. J. Selection of successive tumor lines for metastasis. Nature (Lond.), 242: 148-149, 1973.
14. Schreurs, M. W. J., de Boer, A. J., Figdor, C. G., and Adema, G. J. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res., 58: 2509-2514, 1998.
15. Kupiec-Weglinski, J. W., Austyn, J. M., and Morris, P. Migration patterns of dendritic cells in the mouse. J. Exp. Med., 167: 632-645, 1988.
16. Pargador, A., and Gilboa, E. Bone marrow generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med., 182: 255-260, 1995.
17. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzi, C., Falo, L. D., Melief, C. J., Ildstadt, S. T., Kast, W. M., DeLeo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med., 1: 1297-1302, 1995.
18. Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Tielemans, F., Leo, O., Urbain, J., and Moser, M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol., 24: 605-610, 1994.
19. Celluzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., and Falo, L. D., Jr. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med., 183: 283-287, 1996.
20. van den Eynde, B. J., and van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
21. Kawakami, Y., and Rosenberg, S. A. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immunogene therapy. Int. Rev. Immunol., 14: 173-192, 1997.
22. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J., Therapy of murine tumors with peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
23. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engelman, E. G., and Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
24. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trail: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29: 371-380, 1996.
25. Morse, M. A., Coleman, R. E., Akabani, G., Niehaus, N., Coleman, D., and Lyerly, H. K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res., 59: 56-58, 1999.
26. Barratt-Boyes, S. M., Watkins, S. C., and Finn, O. J. In vivo migration of dendritic cells differentiated in vitra. J. Immunol., 158: 4543-4547, 1997.